EMA Raises Its Expectations on Non-Sterile Contamination Control

Non-sterile contamination control has long been treated as a lesser concern than sterile manufacturing. A new European Medicines Agency question and answer document, EMA/INS/GMP/161750/2026, published on 13 July 2026, closes that gap.

It sets out the technical and organisational measures manufacturers should take to prevent microbial contamination of non-sterile medicinal products, and it points directly to Contamination Control Strategy (CCS) principles as the way to get there. It creates no new law. What it does is gather the existing expectations, state them plainly, and signal where inspectors are now looking.

What the EMA guidance actually says

EMA states that the likelihood of a non-sterile product being contaminated is closely linked to the manufacturer's own processes, and singles out how well cleaning and gowning protocols are followed. It supports the point with a real concern: individual cases of multi-resistant microorganisms found in non-sterile antibiotics.

The message is that a non-sterile label is not a low-risk label. Opportunistic microbes in a final formulation, or a multi-antibiotic-resistant organism, can still harm the patient.

The guidance is deliberate about method. It points to Chapter 5, section 5.10 of the EU GMP guide, which requires products and materials to be protected from microbial contamination at every processing step, and it asks manufacturers to apply Quality Risk Management in the same spirit as Chapter 5.17 to 5.22, with further detail in Annex 1 and Annex 15.

The line that matters most for anyone who has already built a sterile CCS sits in Answer 1: "Manufacturing plants may consider using principles from Contamination Control Strategy (CCS) in accordance with Annex 1 guidance."

EMA is not mandating a full Annex 1 CCS for a non-sterile facility. It is telling non-sterile manufacturers that the CCS way of thinking, holistic, risk-based, evidence-led and continuously reviewed, is the reference model.

The direction of travel is unmistakable.

What non-sterile contamination control now requires

The Q&A separates its measures into technical and organisational. Read together, they describe a contamination programme, not a checklist. The technical measures it calls out:

• Facility, equipment and material-flow design assessed against established limits and driven by quality risk management.

• Cleaning validation that includes microbiological sampling of direct product-contact surfaces, with sampling locations and techniques justified.

• The drying step considered, to prevent contamination from residual humidity in equipment.

• Validated methods for microbial testing of APIs, excipients, water, packaging, equipment, the environment and finished product.

• Water demonstrated suitable for its intended use.

• Validated cleaning and disinfection with suitable agents, cleaning-agent suppliers inside the supplier evaluation programme, and controlled solution expiry dates.

• A phenotypical identification strategy for organisms recovered following a deviation.

The organisational measures sit alongside them:

• Proper gowning, including gloves and facemasks, at critical operations.

• Glove disinfection considered before entering critical areas.

• Regular practical training and assessment for personnel who gown and clean.

• Training of production staff in correct behaviour during production and other critical activities.

• Personnel hygiene and health status closely monitored and reviewed.

• Environmental monitoring to confirm the facility remains suitable for manufacture.

None of this is unfamiliar to a sterile quality team. The point EMA is making is that a non-sterile facility should be able to show the same chain of evidence, from risk assessment, through engineered and procedural controls, to monitoring and governance, proportionate to the actual patient risk. That chain of evidence is exactly what a Contamination Control Strategy is.

Proportionality is the key word

EMA is clear that measures should be proportionate to the risk of the specific product and process. A non-sterile oral solid dose does not need sterile logic imposed on it. What it needs is the same disciplined method, identify the microbial risks at each process step, control them, verify the controls, and monitor that they hold, scaled to the microbiological limits that actually apply, such as those in Ph. Eur. 5.1.4 and the product's route of administration. This is the ICH Q9(R1) proportionality principle made operational, and it is the same principle EMA invokes when it asks for quality risk management in the spirit of Chapter 5.

Building a non-sterile CCS that holds up

Pharmalliance's Contamination Control by Design (CCbD) approach was built holistic from the start, across sterile, bioburden-controlled and non-sterile manufacturing, using one method to produce an Annex 1-structured Contamination Control Strategy proportionate to each product.

When EMA says non-sterile manufacturers may use CCS principles, the work is not reaching for a new tool. It is running a modality the framework already has. A workable non-sterile CCS ties these threads together:

• Quality risk management as the driver of every technical decision, captured in a living risk register.

• Facility, equipment and material-flow controls mapped to the contamination pathways they address.

• Cleaning, disinfection and drying validated, with agents and suppliers controlled.

• Validated microbial test methods, and water shown fit for use.

• Gowning, glove disinfection, hygiene, health and training qualified and recorded.

• Environmental monitoring that confirms the facility stays suitable, trended over time.

• Governance that identifies organisms recovered after a deviation and feeds an annual review.

The value is not a document for each item. It is that the items are linked. A recovered organism in a deviation traces back to the process step that carries its risk, to the control meant to prevent it, and to the monitoring point that should have caught it. When an inspector triangulates across the risk register, the environmental monitoring trend and the deviation log, a connected CCS is where the three already reconcile.

Frequently asked questions

Does the new EMA guidance make a Contamination Control Strategy mandatory for non-sterile products?

No. It does not create new law or a new annex. It gathers existing EU GMP expectations and states that non-sterile manufacturers may use CCS principles from Annex 1. The CCS approach is presented as the reference model, not a legal mandate.

Which regulations does the guidance reference?

EU GMP Chapter 5, including sections 5.10 and 5.17 to 5.22, together with Annex 1, Annex 15, ICH Q9 on quality risk management, and the microbiological limits in Ph. Eur. 5.1.4.

What does proportionate mean for a non-sterile facility?

Controls should match the microbial risk of the specific product, process and route of administration, rather than importing full sterile requirements. The method is the same; the stringency is scaled to the actual patient risk.

About the author

Kieran Falvey is Founder and Managing Director of Pharmalliance Consulting Ltd and the creator of Contamination Control by Design (CCbD). He has more than 20 years designing, building and running pharmaceutical facilities worldwide, across FDA, EMA, TGA, PIC/S and Indian FDA (CDSCO) jurisdictions. Global expert in cGMP Compliance, Remediation and Contamination Control, helping Sterile, Non-Sterile, ATMP and Cosmetic companies navigate cGMP compliance issues.

About Pharmalliance Consulting

Pharmalliance Consulting is a GMP compliance consultancy serving pharmaceutical, sterile, non-sterile, OSD, ATMP and cosmetic manufacturers in Ireland, the UK, the EU and the US. It helps sites identify and remediate GMP risks across facilities, quality systems and contamination control, aligned with HPRA, MHRA, EMA and FDA expectations, turning findings into defensible, inspection-ready practice.

Reviewing your non-sterile contamination controls against the new EMA guidance? Explore our Contamination Control by Design approach and Contamination Prevention services, or contact the team for a review.

Source: European Medicines Agency, technical and organisational measures to prevent microbial contamination of non-sterile medicinal products, EMA/INS/GMP/161750/2026, Human Medicines Division, 13 July 2026.